Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? ; volume:15 ; number:1 ; day:8 ; month:8 ; year:2017 ; pages:1-8 ; date:12.2017
Journal of translational medicine ; 15, Heft 1 (8.8.2017), 1-8, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Ascierto, Paolo A.
- Contributor
-
McArthur, Grant A.
SpringerLink (Online service)
- DOI
-
10.1186/s12967-017-1278-5
- URN
-
urn:nbn:de:1111-201710258040
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ascierto, Paolo A.
- McArthur, Grant A.
- SpringerLink (Online service)
Other Objects (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: A model for testing new agents in combination therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer